Halozyme Therapeutics Inc (HALO) reports a 41% revenue increase, raises 2025 guidance, and advances share repurchase program ...

Halozyme Therapeutics reports a record Q2 2025, with 41% revenue growth. Discover raised guidance, strong catalysts, and shareholder-focused initiatives.

Halozyme jumps 5.3% on second-quarter earnings and revenue beat, fueled by strong royalty growth, and a raised 2025 outlook.

Detailed price information for Halozyme Therapeutic (HALO-Q) from The Globe and Mail including charting and trades.

Halozyme (NASDAQ:HALO) stock rose on Wednesday after the company raised 2025 guidance, prompting a rating upgrade by Morgan Stanley. The company raised 2025 revenue in the range between $1,275M and $1 ...

H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Halozyme (HALO) to $75 from $72 and keeps a Buy rating on the shares ...

Here are a few recent upgrades you may want to pay attention to. Palantir Technologies Palantir Technologies (NYSE: PLTR) ...

The company raised its full-year 2025 guidance, now expecting earnings per share of $6.00-$6.40, well above the consensus estimate of $5.40. Halozyme also increased its revenue forecast to $1.27-1.35 ...